We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.03 | -1.06% | 96.47 | 97.47 | 96.85 | 97.21 | 1,426,052 | 01:00:00 |
From May 2019 to May 2024
By Olivia Bugault
Novartis AG said Monday that the phase 3 of its Ruxcovid study didn't meet its primary endpoint of reducing the number of hospitalized Covid-19 patients with complications.
Data show that ruxolitinib medicine, on top of standard of care therapy, didn't significantly reduce the number of Covid-19 patients in hospital who experienced severe complications including death, respiratory failure requiring mechanical ventilation or admission to the intensive care unit, the pharmaceutical giant said.
"The trial also did not show clinically relevant benefit among secondary and exploratory endpoints including mortality rate by day 29, and time to recovery," Novartis said.
Write to Olivia Bugault at olivia.bugault@wsj.com
(END) Dow Jones Newswires
December 14, 2020 01:52 ET (06:52 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
